Downloadable Resources

  • The DAURISMO Patient Brochure provides helpful information for patients as they start and continue on DAURISMO treatment
Please see Full Prescribing Information, including Boxed Warning.
  • The DAURISMO Dosing & Administration Guide is a resource for physicians, pharmacists, and nurses to support administration of the DAURISMO + LDAC regimen
Please see Full Prescribing Information, including Boxed Warning.
  • In this paper, Dr Jorge Cortes discusses key clinical data from the pivotal BRIGHT AML 1003 study and provides expert commentary, including examples of patient cases, regarding treatment with the DAURISMO + LDAC regimen
Please see Full Prescribing Information, including Boxed Warning.
This website is neither owned nor controlled by Pfizer. Pfizer does not endorse and is not responsible for the content of this site.
Authors: KJ Norsworthy, K By, S Subramaniam, L Zhuang, PL Del Valle, D Przepiorka, Y-L Shen, CM Sheth, C Liu, R Leong, KB Goldberg, AT Farrell, R Pazdur
Clinical Cancer Research. 2019. 25(20):60021-6025.
The FDA-approved labeling for DAURISMO (glasdegib) includes data from this trial. However, it is important to note that some data reported in the publication may be different from or not included in the DAURISMO Prescribing Information.
Please see Full Prescribing Information, including Boxed Warning.
 
Reference
  1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.3.2020. © National Comprehensive Cancer Network, Inc. 2019. All rights reserved. Accessed January 13, 2020. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.